Overview

Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Nepafenac